265 filings
Page 5 of 14
8-K/A
jxn4yucu5h2 ufnh11hf
16 Mar 17
Submission of Matters to a Vote of Security Holders
12:00am
8-K
cv0d bsgde2swf
16 Mar 17
Submission of Matters to a Vote of Security Holders
12:00am
8-K
53imyajo j7zwbabm
9 Mar 17
Submission of Matters to a Vote of Security Holders
12:00am
8-K
6ifdx
3 Mar 17
Immunomedics Board Institutes Measures As Stockholder Fiduciaries to Preserve Their Best Business Judgment to Protect the Rights of All Stockholders
12:00am
8-K
ikcalxt 7bog
2 Mar 17
Immunomedics Outlines Revised Settlement Offer Rejected by Venbio; Announces Actions That Are In the Best Interests of All Stockholders
12:00am
8-K
px579
27 Feb 17
Immunomedics Issues Open Letter Highlighting the Clear Decision
12:00am
8-K
om6c82a7loxxc81t c01
23 Feb 17
Immunomedicsannounces Company’s Immune Checkpoint Inhibitor Enhances Anti-tumor Potency of T-cell-redirecting Bispecific Antibodies
12:00am
8-K
b29lilrza146c 76p5ka
21 Feb 17
Immunomedics Files Federal Lawsuit Against Venbio for Continuing Material Violations of the Federal Securities Laws
12:00am
8-K
aqh04a d3k8oq
21 Feb 17
Other Events
12:00am
8-K
l2ml z2nxn
17 Feb 17
Immunomedics Presents Updated Results with Sacituzumab Govitecan (IMMU-132) In Heavily-pretreated Patients with Metastatic Urothelial Cancer
12:00am
8-K
1gtx ixoa5b
16 Feb 17
Entry into a Material Definitive Agreement
12:00am
8-K
3zuopse1omzc0k lyi
15 Feb 17
Other Events
12:00am
8-K
mgz8 4b8t4th
15 Feb 17
Other Events
12:00am
8-K
sim9ejw74fc07y wse
10 Feb 17
Immunomedics Announces Postponement of 2016 Annual Meeting
12:00am
8-K
66jyubhb0t z85
9 Feb 17
Immunomedics Announces Second Quarter Fiscal 2017 Results and Clinical Program Developments
12:00am
8-K
214jnsxpyqm0kcb5wg0
7 Feb 17
Other Events
12:00am
8-K
wv5 nphr1tqa2ijhvde
2 Feb 17
Immunomedics Mails Letter to Stockholders Highlighting Strength of New Board and Deep Engagement in Robust, Value-Creating Strategic
12:00am
8-K
lzzyy7zzcf9p3u fg2u
30 Jan 17
Immunomedics Sets the Record Straight in New Presentation
12:00am
8-K
uvcdl
27 Jan 17
Immunomedics Issues Statement to Stockholders and Files Investor Presentation
12:00am
8-K
tg1 np50io
24 Jan 17
Other Events
12:00am